Compare Devon Energy Corp (DVN) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Devon Energy Corp vs Vertex Pharmaceuticals Incorporated — how do they compare? Devon Energy Corp trades at $43.5 (market cap $49.52B), while Vertex Pharmaceuticals Incorporated trades at $481.16 (market cap $121.09B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.4× Devon Energy Corp's market cap, and Devon Energy Corp pays a 2.42% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| DVN | VRTX | |
|---|---|---|
Market Cap | $49.52B | $121.09B |
Sector | Energy | Health |
52-Week High | $52.07 | $529.59 |
52-Week Low | $31.74 | $366.54 |
Enterprise Value | $56.29B | $115.83B |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Devon Energy (DVN) trades at $43.40, down 0.75% on the day, with a bullish technical signal and strong analyst support. The stock shows robust fundamentals with a P/E of 11.96 and net income margin of 13.71%, supported by recent earnings beats. Cash flow trends improved in 2025, with net cash flow turning positive to $588 million, while the company navigates post-merger integration following the Coterra acquisition.
Outlook remains positive with a consensus price target of $60.18, implying significant upside. Key opportunities include synergy realization from the merger and disciplined capital allocation. Risks involve activist investor pressure for asset sales, oil price volatility, and execution challenges in achieving projected $2 billion in synergies by 2027.
Vertex Pharmaceuticals (VRTX) trades at $476.31, down 0.82% over 24 hours, with a bullish technical signal despite mixed moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $4.47, and maintains robust profitability with a net income margin of 35.51%. Recent news highlights a $10 billion acquisition of Crinetics Pharmaceuticals, aimed at expanding its endocrinology portfolio with potential peak sales of over $5 billion.
The outlook remains positive with analyst consensus favoring a buy rating (83.92%) and a price target of $538, suggesting 13% upside. Key risks include integration challenges from the Crinetics deal and reliance on cystic fibrosis treatments, while strong cash flow and earnings growth support long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
